NOVAVAX

[dothedd]

Novavax Announces Ebola Vaccine Development Program at the  

8th Vaccine and ISV Conference in Philadelphia 

• First Ebola Vaccine Candidate based on the 2014 Guinea Ebola Strain Genetic
Sequence
• Robust immune responses demonstrated in preclinical studies; exceptional
responses when used with Novavax’ Matrix-M™ adjuvant
• Non-human primate study initiated
• GMP manufacture initiated; Scaled-up manufacturing to begin 1st quarter 2015
• Phase 1 clinical trial anticipated to start in December 2014
Gaithersburg, MD (October 27, 2014) – Novavax, Inc. (NASDAQ: NVAX) today announced
that Gale Smith, Ph.D., Vice President of Vaccine Development at Novavax, presented at the 8th
Vaccine and ISV Conference in Philadelphia on Sunday, October 26. Dr. Smith’s presentation
was titled: 2014 Guinea Ebola Virus Recombinant Glycoprotein (GP) Nanoparticle Vaccine was Highly Immunogenic and Cross-Neutralized 1976 Virus GP Pseudovirus.

Dr. Smith reported on Novavax’ Ebola GP recombinant nanoparticle vaccine candidate (EBOV
GP Vaccine), which is based on the 2014 Guinea Ebola strain that is responsible for the current Ebola disease epidemic in West Africa. In preclinical models, the EBOV GP Vaccine induced antibody titers against the homologous 2014 Guinea Ebola GP in the range of 103 to 104 (ELISA EC 90). Aluminum phosphate as an adjuvant resulted in a modest adjuvant effect; however, the Company’s proprietary adjuvant Matrix-M™ enhanced anti-Ebola GP responses by 10 to 100fold, inducing Ebola GP antibody titers of 105 to 106 (ELISA EC90). Importantly, EBOV GP vaccine plus Matrix-M induced serum cross-neutralization to the older Ebola 1976 (Mayinga) GP-VSV pseudotype. The EBOV GP Vaccine, adjuvanted with Novavax’ Matrix-M adjuvant, induced anti-GP ELISA and neutralizing antibody levels well within ranges reported to protect against Ebola viruses in rodent and non-human primate models.

“We are developing our recombinant Ebola GP vaccine using the same platform we used to
develop vaccine candidates against several pathogens including respiratory syncytial virus
(RSV), seasonal and pandemic influenza, and Middle Eastern Respiratory Syndrome (MERS),” said Stanley C. Erck, President and CEO. “Our proprietary platform allows us to quickly develop, and manufacture an Ebola vaccine candidate at large scale, which we believe can provide a necessary tool to fight this global health crisis.”

Novavax has recently initiated a non-human primate study and expects to initiate a Phase 1
clinical trial in December 2014 to evaluate the safety and immunogenicity of the EBOV GP
Vaccine in ascending doses, with and without the Matrix-M adjuvant, in approximately 150
subjects. Plans to demonstrate the safety and efficacy in a large-scale global clinical trial will be developed based on data from the Phase 1 trial and in collaboration with global regulatory authorities and world health agencies.

“We used the recently published Guinea 2014 Ebola strain genetic sequence1 to create a highly purified, correctly folded, Ebola GP Vaccine in only a few weeks,” said Gregory Glenn, M.D., SVP, Research and Development at Novavax. “The data presented today provides scientific validation that our technology platform can respond to emerging viral threats in an extremely efficient and effective manner. We look forward to the results of our non-human primate studyand the initiation of a Phase 1 clinical trial in the near future.”

The Novavax EBOV GP Vaccine may also address other key requirements for a successful
vaccine against this viral threat: (1) like Novavax’ other recombinant vaccines, it appears to not require frozen storage allowing for easier transport and more efficient global distribution; (2) manufacturing could be rapidly scaled to millions of doses a month, based on the Company’s experience in scale-up and manufacturing with its other nanoparticle vaccine candidates, and; (3) the preclinical data suggest that the Matrix-M adjuvant enhances immunogenicity with lower doses of antigen, which would further leverage the company’s ability to manufacture and supply significant doses.

CONTINUED:
www.novavax.com/download/releases/Novavax%20Announces%20Ebola%20Vaccine%20Development%20Program%20at%20the%208th%20Vaccine%20and%20ISV%20Conference%20in%20Philadelphia.pdf

[dothedd]

Novavax sees 'several billion-dollar global opportunity' as it plans Ebola vaccine clinical trial by year-end

Oct 30, 2014, 2:42pm EDT

Novavax Inc.'s singular drug development approach to a possible Ebola vaccine may not only help stop the spread of a future pandemic but also reap major bottom-line rewards.

That's what CFO Barclay "Buck" Phillips told me this week after the Gaithersburg-based company announced it planned to begin Phase 1 clinical trials by December. Novavax announced this week at the 8th Vaccine and ISV Conference in Philadelphia that it's the only company targeting the newest strain of the virus which emerged in Guinea this year and has killed thousands in West Africa.

"Clearly this is a pathogen we need to address," said Phillips.
The Ebola vaccine, he added, is potentially a "several billion-dollar global opportunity."

Multiple vaccines and treatments for Ebola are under development around the region. Rockville-based biopharmaceutical company Emergent BioSolutions Inc. could begin manufacturing its experimental Ebola drug, ZMapp, at its Baltimore facility. The feds recently gave $14.4 million to Baltimore's Profectus BioSciences Inc. for work on an Ebola vaccine. And earlier this month, the National Institutes of Health announced it was beginning human trials for an Ebola vaccine.

Phillips told me Novavax is using a different strategy because it can make a gene sequence of the protein that surrounds a virus and build the vaccine to trigger an immune system response completely based on that protein. Other companies still rely on using a virus of some sort to trigger that response, he said.

Novavax also found its adjuvant technology, or the substance it created to enhance immune system responses to its vaccines, worked well with the vaccine candidate, Phillips said.

A Phase 1 trial would be conducted in the U.S. with healthy volunteers to ensure the vaccine is well tolerated and that blood samples indicate the expected immune response. If that is successful, a Phase Two trial would likely be started on individuals in Africa as early as late next year, Phillips said.

But predicting timelines is difficult in drug and vaccine development — and barring any troubles moving through the regulatory process, this particular vaccine candidate would still be several years away from market.

The company has yet to bring a vaccine to the market and last year posted a $52 million loss on $20.9 million revenue. But the company says it's getting closer to changing that. Earlier this year, the company raised $115 million by selling 28.75 million shares of its common stock, with plans to channel the money into research. Novavax is furthest along in developing a vaccine to protect against respiratory syncytial virus, or RSV. It's starting multiple Phase 2 clinical trials this year for the vaccine.

When it comes to Novavax's work on the Ebola vaccine, Phillips said he is optimistic.

"So far, the safety and tolerability has been extremely high. We do believe we'll have a safe product and we know we'll have a strong immunological response," he said.

[dothedd]

Thursday 

Novavax, Inc. (NVAX) -NasdaqGS 
5.63 Up 0.22(4.07%) 4:00PM EDT
After Hours : 5.63 Up 0.00 (0.01%) 4:37PM EDT


5.71  0.30(5.47%) 9:37AM EDT
5.69  0.28(5.18%) 9:37AM EDT
5.68  0.28(5.18%) 9:37AM EDT
5.67  0.26(4.82%) 9:37AM EDT
5.66  0.25(4.62%) 9:39AM
5.70  0.29(5.29%) 9:39AM
5.69  0.28(5.12%) 9:39AM
5.68  0.28(5.08%) 9:39AM
5.68  0.28(5.08%) 9:39AM
5.67  0.26(4.75%) 9:40AM EDT
5.71  0.30(5.55%) 9:53AM EDT
5.69  0.28(5.18%) 9:54AM EDT
5.68  0.27(5.05%) 9:54AM EDT
5.58  0.17(3.14%) 10:00AM EDT
5.59  0.18(3.33%) 10:03AM EDT
5.61  0.20(3.70%) 10:05AM EDT
5.65  0.24(4.44%) 10:06AM EDT 
5.63  0.22(4.07%) 10:06AM EDT 
5.65+0.24(4.44%)9:17AM EST
5.66  0.25(4.55%) 10:18AM EDT
5.67  0.25(4.63%) 10:28AM EDT
5.66  0.25(4.63%) 10:28AM EDT
5.70  0.29(5.36%) 10:52AM EDT
5.71  0.31(5.73%) 10:53AM EDT
5.72  0.31(5.73%) 10:53AM EDT
5.69  0.28(5.18%) 10:56AM EDT
5.65  0.24(4.44%) 10:58AM ED
5.64  0.23(4.25%) 11:50AM EDT
5.66  0.25(4.62%) 11:56AM EDT
5.67  0.26(4.81%) 12:20PM EDT 
5.64  0.23(4.27%) 2:13PM EDT

Novavax, Inc. (NVAX)

5.63 
 0.22(4.07%) 4:00PM EDT
After Hours : 5.63 
 0.00 (0.01%) 4:37PM EDT

[dothedd]

8th Vaccine & ISV Congress 

26-28 October 2014 

Philadelphia, USA 

www.novavax.com/download/file/Novavax%20EBOLA%20GP%20ISV%20Meeting%2026Oct14%20FINAL(1).pdf

[dothedd]

• In Sierra Leone May 2014 at funeral of a Guinea EVD case, attendees were infected with two distinct Ebola cluster 1,2 viruses leading to cluster 3 sustained human-to-human transmission.

• “Because many of the mutations alter protein sequences and other biologically meaningful targets, they should be monitored for impact on diagnostics, vaccines, and therapies critical to outbreak response.”


www.novavax.com/download/file/Novavax%20EBOLA%20GP%20ISV%20Meeting%2026Oct14%20FINAL(1).pdf

[dothedd]

Analyst Firms Making Recommendations 

FBR CAP MARKETS LADENBERG THALM PIPER JAFFRAY WEDBUSH SECURIT

STRONG BUY

Read more: www.nasdaq.com/symbol/nvax/recommendations#ixzz3I3pW59vR

[dothedd]

Novavax Third Quarter 2014 Financial Results
Gaithersburg, Maryland
November 5, 2014, 4:30 p.m. ET
Dial-in: 1-877- 212-6076 (domestic) or 1-707-287-9331 (international)
Conference ID: 27652087
 

Conference Call
Novavax management will host its quarterly conference call today at 4:30 p.m. EDT. The dial-in
number for the conference call is 1 [phone] (U.S. or Canada) or 1 [phone]
(international). A webcast of the conference call can also be accessed via a link on the home
page of the Novavax website (novavax.com) or through the “Investor Info”/“Events” tab on the
Novavax website.
A replay of the conference call will be available starting at 6:31 p.m. on November 5, 2014 until
midnight November 12, 2014. To access the replay by telephone, dial 1 [phone]
(domestic) or 1 [phone] (international) and use passcode 27652087. The replay will also
be available as a webcast and can be found on the “Investor Info”/”Events” on the Novavax
website.


Novavax to Host Conference Call to Discuss Third Quarter 2014 Financial
Results on November 5, 2014
Gaithersburg, MD (October 30, 2014)–/GlobeNewswire/-Novavax, Inc. (Nasdaq: NVAX), a
clinical-stage biopharmaceutical company focused on the discovery, development and
commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it will
report its financial results for the third quarter of 2014 on Wednesday, November 5, 2014, after
market close.
In addition, management will host a conference call, to discuss the quarterly financial results and
provide an update on corporate activities.
Conference call details are as follows:
Date: November 5, 2014
Time: 4:30 PM US eastern time
Dial-in number: 1 [phone] (domestic) or 1 [phone] (international)
Via Web: www.novavax.com
Conference call replay:
Dates: Starting at 6:31pm on November 5, 2014 until midnight November 12, 2014
Dial-in number: 1 [phone] (domestic) or 1 [phone] (international)
Passcode: 27652087
Via-Web: www.novavax.com, “Investor Info”/”Events”
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating novel
vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using
innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces
vaccine candidates to efficiently and effectively respond to both known and newly emergent
diseases. Additional information about Novavax is available on the company’s website,
novavax.com.
Contact: Barclay Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000

Novavax Reports Third Quarter 2014 Financial Results
11/05/14
Novavax to Host Conference Call to Discuss Third Quarter 2014 Financial Results on November 5, 2014
10/30/14

[dothedd]

Novavax and Collaborators Make Multiple Presentations at the  

9th International Respiratory Syncytial Virus Symposium  

in South Africa, November 9-13, 2014 

Gaithersburg, MD (November 7, 2014) - Novavax, Inc. (Nasdaq: NVAX), a clinical-stage
biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that representatives of Novavax, along with a number of its research collaborators, will be making multiple oral
presentations and poster presentations related to Novavax’ RSV F-protein nanoparticle vaccine candidate (RSV F Vaccine) at the 9th International Respiratory Syncytial Virus Symposium to be held November 9 – 13, 2014 in Stellenbosch, South Africa.

Poster, presentation titles, and presenters are listed below:
• “Maternal Immunization of Pregnant Baboons with the RSV F Nanoparticle Vaccine
Leads to Transplacental Transfer of High Affinity Functional Antibodies in Infants.”
Robert C. Welliver, M.D., Professor of Pediatrics and Section Chief, The University of
Oklahoma Health Sciences Center
• “Placental Transfer of Anti-RSV F Maternal Antibody in Rabbits and Guinea Pigs
Immunized with an RSV F Nanoparticle Vaccine Co-administered with Aluminum
Phosphate.”
Hanxin Lu, Ph.D., Senior Scientist, Novavax, Inc.
• “A Phase II Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to
Evaluate the Immunogenicity and Safety of Multiple Formulations of an RSV F
Nanoparticle Vaccine with Aluminum, in Healthy Women of Child-bearing Age.”
Nigel Thomas, Ph.D., Vice President, Clinical Operations, Novavax, Inc.
• “Immunogenicity of the RSV F Nanoparticle Vaccine and Induction of Palivizumab
Competing Antibodies: Review of Immunogenicity Data and Consideration of the
Clinical Relevance.”
Gregory Glenn, M.D., Senior Vice President, Research and Development, Novavax, Inc.
• “Cotton Rats Vaccinated with RSV F-Protein Nanoparticle Vaccine are Protected from
Infection with RSV Wild Type and Palivizumab Escape Mutant Virus.”
Pedro Piedra, M.D., Professor of Molecular Virology and Microbiology, Baylor College
of Medicine

About RSV
RSV is a widespread disease that causes infections of the lower respiratory tract. While RSV affects individuals of all ages, it acutely impacts infants, the elderly, young children and others with compromised immune systems. RSV is the number one cause of hospitalization in infants ages 0 to 12 months in the U.S. and is a significant cause of infant morbidity and mortality globally. Current estimates indicate that RSV is responsible for over 30 million new acute lower respiratory infection episodes and between 150,000 and 200,000 deaths in children under five years old. In the U.S., nearly all children become infected with RSV before they are two years old; it has been associated with 20% of hospitalizations and 15% of office visits for acute respiratory infection in young children. The World Health Organization (WHO) estimates that the global disease burden for RSV is 64 million cases. Because there is no approved prophylactic vaccine, an RSV vaccine has the potential to protect millions of patients from this far-reaching unmet medical need.

[dothedd]

Novavax Initiates Phase 1 Clinical Trial of RSV F Vaccine in Pediatric Subjects 

Gaithersburg, MD (November 10, 2014)–/GlobeNewswire/-Novavax, Inc. (Nasdaq: NVAX), a
clinical-stage biopharmaceutical company focused on the discovery, development and
commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy children, the first study of this vaccine candidate to be conducted in a pediatric population.

The trial, which is being conducted in Canada, is a randomized, observer-blinded, dose-ranging Phase 1 study to evaluate the safety and immunogenicity of the RSV F Vaccine, with or without aluminum phosphate adjuvant, in 150 healthy pediatric subjects two to six years of age. In addition to the trial’s primary goal of evaluating safety in this population, the study will also evaluate immunogenicity as measured by concentrations of serum IgG antibodies to the RSV fusion, or F-protein, palivizumab-competing antibody titers and RSV microneutralization titers.

“Today’s announcement of the initiation of the Phase 1 RSV F Vaccine pediatric trial, deliverson our stated goal of starting RSV F Vaccine trials in all three of our target populations, duringthe third and fourth quarters of 2014. With the initiation of clinical trials in pregnant women, elderly subjects and children, we position our RSV F Vaccine franchise to deliver important clinical results in the second and third quarter of 2015.” said Stanley C. Erck, President and CEO of Novavax.

“RSV is a significant cause of pediatric respiratory disease, including pneumonia, bronchiolitis and recurrent wheezing. The ability to prevent RSV-related lower respiratory disease in the pediatric population via immunization is an important public health goal.” said Dr. GregoryGlenn, SVP, Research and Development at Novavax. “We believe this clinical trial is an important step forward in addressing that goal.”

About RSV
RSV is a major respiratory pathogen with a significant burden of disease in the very young and in the elderly. In healthy adults, RSV infections are generally mild to moderate in severity, but may be more severe in infants and young children as well as the elderly and adults with underlying chronic cardiac or pulmonary disease. Globally, RSV is a common cause of childhood respiratory infection, with a disease burden of 64 million cases and approximately 160,000 deaths annually. Severe RSV disease results in 3.4 million hospital admissions per year globally and disproportionately affects infants below six months of age. In infants, toddlers and young pre-school and school-age children, RSV infections result in the need for frequent medical care, including ER and office visits and are associated with increased recurrent wheezing that can persist for years. It is also estimated that between 11,000 to 17,000 elderly and high risk adults die of RSV infection or its complications annually in the U.S., and up to 180,000 are hospitalized for serious respiratory symptoms. Currently, there is no approved RSV vaccine available for any of these populations.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating novel
vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Additional information about Novavax is available on the company’s website, novavax.com.

[dothedd]

U.S. Senate Committee on Appropriations 

Hearing on U.S. Government Response to Ebola Outbreak 

Testimony: Novavax, Inc. 

Wednesday, November 12, 2014 

Chairwoman Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide written testimony on behalf of Novavax, Inc. regarding our efforts to respond to the current Ebola crisis by rapidly advancing the development and production of a promising vaccine candidate.

Novavax is a clinical‐stage biopharmaceutical company based in Maryland, focused on the
discovery, development and commercialization of recombinant nanoparticle vaccines and
adjuvants. Our principal vaccine candidates currently in clinical development include the
world’s most advanced vaccine for respiratory syncytial virus (“RSV”) and vaccines against
seasonal influenza and pandemic influenza, all of which are in Phase 2 clinical trials.

At Novavax, we use our technology to produce vaccine candidates that can rapidly respond to emerging diseases. For example, under our $179 million HHS/BARDA contract, we have
developed and delivered compelling safety and immunogenicity data in humans for vaccines
against two pandemic influenza strains: H5N1 and H7N9. We also have been monitoring other emerging diseases, such as Middle East Respiratory Syndrome (known as “MERS”), a novel coronavirus first identified in September 2012, as well as the recent outbreak of Ebola virus disease in West Africa.

It is worth noting that five (5) strains of Ebola have been identified, and that the strain currently afflicting West Africa is known as the “Guinea strain”, which was identified in August 2014.

With the speed and flexibility of our platform, we have been able to customize our vaccine to the currently circulating strain. While current publicly known vaccine approaches target earlier strains of the virus, Novavax’ Ebola vaccine candidate is the first, and currently only, reported Ebola vaccine produced using the genetic sequence of the Guinea strain. Our Ebola vaccine has recently been successfully tested in both rodent and rabbit pre‐clinical models. We have also tested the vaccine with our Matrix‐M™ adjuvant in these same pre‐clinical models, with results showing that Matrix‐M appears to significantly contribute to enhanced immunogenicity and induction of neutralizing antibodies.

Due to the urgent global public health need for an Ebola vaccine, Novavax feels that it
important to further develop our Ebola vaccine candidate. Therefore, we recently publicly
announced our initiation of a non‐human primate study and our expectation to initiate a Phase 1 clinical trial in December 2014 that will evaluate the safety and immunogenicity of our vaccine candidate in ascending doses, with and without our Matrix‐M adjuvant. Subsequent clinical studies will be designed following the data from the non‐human primate study and the Phase 1 clinical trial.

Page 2 of 3 

Despite heroic efforts by numerous global health agencies and product developers,
development of vaccination strategies for emerging pathogens like Ebola are particularly
challenging because of the sudden emergence and rapid dissemination of such diseases, as well as the long process of traditional vaccine development. Although the U.S. government is working with health agencies and industry players to stream‐line and fast‐track regulatory requirement, the U.S. government should also prioritize appropriations for vaccine platform technologies that are rapidly adaptable to novel and re‐emerging pathogens. Novavax offers the following recommendations to the U.S. government:

1. Invest in Flexible, Rapid and Proven Vaccine Technologies. An effective response requires
willingness to adopt vaccine technologies that demonstrate flexibility to make the first
doses available on a rapid timeline from the identification of pathogen to first doses
available.

This approach would also minimize time and investment dollars in future emergencies. For
example, Novavax’ technology allows us to monitor reports concerning emerging diseases
and, as soon as the genetic sequence of the pathogen is published, proceed from gene to
human clinical data in comparatively short periods of time.

Novavax demonstrated this capability last year in response to the H7N9 pandemic influenza
strain, which was first recognized by Chinese health authorities as a potential pandemic
influenza threat in late March 2013. In a three‐month period, we developed a vaccine
antigen, conducted multiple animal studies and initiated the world’s first Phase 1 clinical
trial of a vaccine against an H7N9 influenza strain. Our clinical results were published in
November 2013 in The New England Journal of Medicine, where we showed that we
achieved protective levels from vaccinations within just 116 days of the announcement of
the H7N9 outbreak.

Similarly, we have cloned the current Guinea strain of Ebola now circulating in West Africa,
and we expect to be in a clinical trial next month (December 2014). Our platform affords the U.S. government the opportunity to address not only Ebola, but other emerging infectious diseases, with a timely response that we believe can minimize future risks, as well as expenditures, for the benefit of citizens of the United States and the world.

2. Invest in Scalable Technologies. Technology that can rapidly produce the first doses of
vaccine is critical, but effective vaccine platforms must also be rapidly scalable to produce
sufficient vaccine to move through the development process and be deployed for effective
use. As was seen with the antibody therapeutic developed by ZMapp, promising solutions
can be handicapped by the lack of expandable production processes. The Novavax platform
uses insect cell culture and disposable manufacturing equipment, both of which have
proven to be rapidly scalable, to produce thousands up to potentially millions of vaccine
doses within a matter of months.

3. Continue to Invest in Adjuvant Technologies to Expand Supply and Broaden Protection.


PAGE 3 of 3

Vaccines for highly pathogenic viruses, such as Ebola, should be made rapidly and in
conjunction with the use of adjuvants. Adjuvants are immunostimulating molecules,
designed to do one or more of the following: (1) improve the immunogenicity (i.e., to
increase protection), (2) provide antigen dose‐sparing (i.e., lower antigen doses increase
number of doses available for distribution), and (3) broaden the scope of protection (e.g.,
cross‐strain protection) as pathogens change and mutate. Several NIH and BARDA funded
programs for pandemic influenza vaccines have demonstrated the significant dose‐sparing
potential of adjuvants when combined with vaccines. Novavax’ own pandemic influenza
program has demonstrated that certain adjuvants provide both immunogenicity and dose‐
sparing benefits compared to unadjuvanted vaccines. Moreover, Novavax pandemic
influenza vaccines have demonstrated that certain adjuvants contribute to the broader
cross‐reactivity to different strains of pandemic influenza.

Given the concern about manufacturing sufficient numbers of doses in a timely manner,
Novavax recommends that the U.S. government support the development of Ebola vaccines
with dose‐sparing adjuvants so more vaccine doses can be available in less time.
Novavax has demonstrated the ability to rapidly and successfully advance vaccine candidates from gene sequence to clinical trials. We are currently committing our own human and technological capital in order to demonstrate our Ebola vaccine is worthy of consideration as a possible solution for this immediate health crisis. In addition, our platform technology can provide cost‐effective and timely solutions to address future emerging disease threats.

Such efforts necessitate that the U.S. government ensures that emergency programs for Ebola products continue to be funded, but at the same time the U.S. government should evaluate the available technologies to address its longer‐term needs to develop solutions to future emerging threats. Novavax agrees with BIO that to prepare for the full range of potential threats, we must prioritize funding for Project BioShield, BARDA, pandemic influenza, the SNS, and other programs that are essential to public health preparedness this year and in coming years. These programs simply cannot be funded only after a disaster hits; such reactionary thinking would put lives at risk. The U.S. biotechnology industry is uniquely capable of advancing early scientific innovations to products that can be safely and effectively used, and it is time to make the necessary investments to address Ebola and other newly emerging, novel infectious diseases with investments in companies capable of making new vaccines, such as Novavax.

[dothedd]

Intraday Performance Summary

Chart for Novavax, Inc. (NVAX)
Novavax, Inc. NVAX Up 1.53%
Biotechnology ^YHOh788 Down 0.62%

[dothedd]

Industry: Biotechnology Get Industry for:
NVAX Sector / Industry Membership
Sector: Healthcare
Industry: Biotechnology
Intraday Performance Summary

Novavax, Inc. NVAX Up 0.95%
Biotechnology ^YHOh788 Down 0.62%

[dothedd]

$NVAX Institutional Holdings: 59.84%

Top Institutional Holders
Holder Shares % Out Value* Reported
Price (T.Rowe) Associates Inc 10,214,700 4.28 47,191,914 Jun 30, 2014
BlackRock Fund Advisors 8,043,390 3.37 33,540,936 Sep 30, 2014
Wells Fargo & Company 7,300,918 3.06 30,444,828 Sep 30, 2014
Invesco Ltd. 7,071,863 2.97 32,672,007 Jun 30, 2014
Vanguard Group, Inc. (The) 7,082,027 2.97 29,532,052 Sep 30, 2014
State Street Corporation 6,952,523 2.92 28,992,020 Sep 30, 2014
BlackRock Institutional Trust Company, N.A. 6,650,277 2.79 27,731,655 Sep 30, 2014
RA Capital Management, LLC 6,661,731 2.79 30,777,197 Jun 30, 2014
FMR, LLC 24,914,161 10.45 115,103,423 Jun 30, 2014
Camber Capital Management, LLC 4,750,000 1.99 21,945,000 Jun 30, 2014

Top Mutual Fund Holders
Holder Shares % Out Value* Reported
Fidelity Select Portfolios - Biotechnology 14,411,821 6.04 62,547,303 Jul 31, 2014
Powershares Exhg Traded Fd-Dynamic Pharmaceuticals Port 7,409,272 3.11 34,749,485 Aug 31, 2014
Price (T.Rowe) Health Sciences Fund 4,622,400 1.94 21,355,488 Jun 30, 2014
Wells Fargo Advantage Discovery Fd 4,113,967 1.73 19,294,505 Aug 31, 2014
Fidelity Small Cap Opportunities Fund 3,775,362 1.58 16,385,071 Jul 31, 2014
Vanguard Total Stock Market Index Fund 3,538,613 1.48 16,348,392 Jun 30, 2014
iShares Russell 2000 ETF 3,408,963 1.43 15,988,036 Aug 31, 2014
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF 3,207,982 1.35 13,922,641 Jul 31, 2014
iShares NASDAQ Biotechnology ETF 2,789,164 1.17 13,081,179 Aug 31, 2014
Fidelity Advisor Biotechnology Fund 2,301,331 0.97 9,987,776 Jul 31, 2014

[dothedd]

The market has done this just 4 times in the last 20 years
By Lawrence Lewitinn

Something rare and potentially very dangerous is happening in the market right now. And if history is any indication, it could spell short-term pain.

finance.yahoo.com/blogs/talking-numbers/the-market-has-done-this-just-4-times-in-the-last-20-years-232157220.html

INTERESTING!

[dothedd]

Novavax, Inc. (NVAX) -NasdaqGS
5.28 Up 0.09(1.73%) 4:00PM EST
After Hours : 5.28 0.00 (0.00%) 4:00PM EST - Nasdaq Real Time Price

[dothedd]

INTERESTING ... 

GSK ready to ax hundreds in U.S., sources tell Bloomberg
December 1, 2014

GlaxoSmithKline ($GSK) is making big cost cuts to boost its finances next year as sales of its $8.25 billion asthma med Advair are deflated by competition, generic and otherwise. With the U.S. being the biggest market for the drug, where do you think it will look to make cuts? Yes, reports are that hundreds of jobs are on the line in the U.S. and the culling will be announced this week.


GSK CEO Andrew Witty
CEO Andrew Witty said cuts would have to be made to reduce costs by £1 billion (about $1.6 billion) over the next 3 years when the company reported disappointing Q3 revenues in October. The company said that headcount reductions would be announced after the company had meetings with employees, and sources are telling Bloomberg the big reveal will be made this week by Deirdre Connelly, president of North American operations. She has a meeting set Wednesday to talk with U.S. employees.

The why of the matter is clear. Advair is GSK's biggest seller and analysts are pegging sales of the asthma drug to be off 30% next year, Bloomberg reports. Advair is already off patent but has held its own since its inhaler device is hard to copy. Competition from Teva Pharmaceutical Industries ($TEVA) and Novartis' ($NVS) Sandoz unit are taking market share in Europe while in the U.S. AstraZeneca ($AZN) has been making progress with its own respiratory drug Symbicort. Express Scripts ($ESRX) this year made things worse when it gave Symbicort a place in its exclusionary formulary this year while dropping Advair. GSK acknowledged in its Q3 report that it expected sales to continue to slide "in line with recent trends."

It is not as if cutting jobs and costs is new at GSK. The current reduction plan comes on top of a £1 billion reduction program announced early in 2013. Those reductions were mainly to come from manufacturing and R&, with job cuts targeted in Europe.

Witty has assured investors that respiratory drug sales will return to growth in 2016 as the company rolls out new meds. Anoro and Breo are on the market, and GSK has some other new respiratory drugs it expects to be approved soon.

[dothedd]

LIVE WEBCAST

GAITHERSBURG, Md., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 11:00 a.m. ET in New York, NY at The New York Palace Hotel.

A live webcast link for the presentation will be available via the company's website at www.novavax.com under Investor Info/Events.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
money.cnn.com/news/newsfeeds/articles/globenewswire/10110048.htm


LIVE WEBCAST LINK:  www.media-server.com/m/p/a5tsn5ef


5.35  0.03(0.56%) 10:39AM EST
5.34  0.02(0.47%) 10:40AM EST
5.47  0.15(2.82%) 11:58AM EST 
5.45  0.13(2.45%) 12:36PM EST 
5.45  0.13(2.50%) 12:43PM EST
5.46  0.14(2.63%) 12:44PM EST 
5.47  0.15(2.82%) 12:30PM EST 
LIVE WEBCAST LINK:  www.media-server.com/m/p/a5tsn5ef

[dothedd]

ALERT

Hackers With Apparent Investment Banking Background Target Biotech
Nicole Perlroth
Monday, 1 Dec 2014 | 8:31 AM ET

www.cnbc.com/id/102227237?__source=yahoo%7Cfinance%7Cinline%7Cstory%7Cstory&par=yahoo&doc=102234825#.

[dothedd]

How to fend off malicious hacking 

Tuesday, 2 Dec 2014 | 5:30 AM ET 

Back up your drives and take control of your information, as the cost of backing up information is much cheaper than losing key data says Pat O'Malley, CFO of Seagate Tech.

video.cnbc.com/gallery/?video=3000335651

[dothedd]

THURSDAY
12/4/2014


5.35  0.07(1.26%) 9:32AM EST
5.33  0.09(1.66%) 9:36AM EST
5.32  0.10(1.83%) 9:36AM EST
5.35  0.07(1.26%) 9:44AM EST
5.36  0.07(1.29%) 9:45AM EST
5.33  0.09(1.66%) 9:50AM EST
5.33  0.09(1.66%) 9:54AM EST
5.34  0.07(1.29%) 10:04AM ES
5.35  0.07(1.29%) 10:04AM ES
5.36  0.06(1.08%) 10:05AM EST
5.32  0.10(1.79%) 10:11AM EST
5.34  0.08(1.40%) 10:14AM EST
5.35  0.07(1.29%) 10:16AM EST
5.34  0.08(1.40%) 10:23AM EST
5.28  0.04(0.75%) 10:22AM EST 
5.33  0.09(1.66%) 10:30AM EST
5.32  0.10(1.75%) 10:31AM EST
5.33  0.09(1.66%) 10:32AM EST
5.31  0.11(2.03%) 10:32AM EST
5.31  0.11(2.08%) 10:38AM EST
5.30  0.12(2.22%) 10:45AM EST


12/3/14  jcpafonso.blogspot.pt/p/bullish-macd-crossovers_4.html

[dothedd]

U.S. Senate Committee on Appropriations
Hearing on U.S. Government Response to Ebola Outbreak

Testimony: Novavax, Inc.

Wednesday, November 12, 2014 

Chairwoman Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide written testimony on behalf of Novavax, Inc. regarding our efforts to respond to the current Ebola crisis by rapidly advancing the development and production of a promising vaccine candidate.

Novavax is a clinical‐stage biopharmaceutical company based in Maryland, focused on the
discovery, development and commercialization of recombinant nanoparticle vaccines and
adjuvants. Our principal vaccine candidates currently in clinical development include the
world’s most advanced vaccine for respiratory syncytial virus (“RSV”) and vaccines against
seasonal influenza and pandemic influenza, all of which are in Phase 2 clinical trials.

At Novavax, we use our technology to produce vaccine candidates that can rapidly respond to emerging diseases. For example, under our $179 million HHS/BARDA contract, we have
developed and delivered compelling safety and immunogenicity data in humans for vaccines
against two pandemic influenza strains: H5N1 and H7N9. We also have been monitoring other emerging diseases, such as Middle East Respiratory Syndrome (known as “MERS”), a novel coronavirus first identified in September 2012, as well as the recent outbreak of Ebola virus disease in West Africa.

It is worth noting that five (5) strains of Ebola have been identified, and that the strain currently afflicting West Africa is known as the “Guinea strain”, which was identified in August 2014.

With the speed and flexibility of our platform, we have been able to customize our vaccine to
the currently circulating strain. While current publicly known vaccine approaches target earlier strains of the virus, Novavax’ Ebola vaccine candidate is the first, and currently only, reported Ebola vaccine produced using the genetic sequence of the Guinea strain. Our Ebola vaccine has recently been successfully tested in both rodent and rabbit pre‐clinical models.


We have also tested the vaccine with our Matrix‐M™ adjuvant in these same pre‐clinical models, with results showing that Matrix‐M appears to significantly contribute to enhanced immunogenicity and induction of neutralizing antibodies. 
 
Due to the urgent global public health need for an Ebola vaccine, Novavax feels that it
important to further develop our Ebola vaccine candidate. Therefore, we recently publicly
announced our initiation of a non‐human primate study and our expectation to initiate a Phase 1 clinical trial in December 2014 that will evaluate the safety and immunogenicity of our vaccine candidate in ascending doses, with and without our Matrix‐M adjuvant. Subsequent clinical studies will be designed following the data from the non‐human primate study and the Phase 1 clinical trial.

www.appropriations.senate.gov/sites/default/files/hearings/Novavax.pdf

[dothedd]

Novavax Inc (NASDAQ:NVAX) shares are expected to touch $9.5 in the short term. This short term price target has been shared by 5 analysts. However, the standard deviation of short term price estimate has been valued at 1.41. The target price could hit $11 on the higher end and $7 on the lower end. Novavax Inc (NASDAQ:NVAX) : Optimism-led buying helped Novavax Inc (NASDAQ:NVAX)post gains of 0.19% or 0.01 points. The mood remained fairly bullish throughout the day and no significant downmove or selling pressure was witnessed. During the day, the shares fluctuated in $5.17-$5.29 but finally closed higher at $5.26. The shares had closed the previous day trading session at $5.25. The 52-week high of Novavax Inc (NASDAQ:NVAX) is at $6.95. The volume for the day was recorded at 1,984,445 shares. Currently, there are 238,478,000 outstanding shares and the company has a market cap of $1,254 million. The 52-week low of the shares is at $3.33.


www.marketsinsider.com/analyst-update-on-short-term-price-targetwalgreen-company-novavax-inc-2/321376/

[dothedd]

NVAX – Novavax, Inc. – Weekly Chart Showing Uptrend

by gameofstocks
DECEMBER 9, 2014


gameofstocks.com/nvax-novavax-inc-weekly-chart-showing-uptrend/



gameofstocks.com/category/trend-reversals/

[dothedd]

Friday, December 12, 2014, 8:00:00 AM, 9 hours, 30 minutes.

This event is available in High Definition. (HD)

Description: The goal of this workshop, which is co-sponsored by FDA, NIAID, DOD, CDC, and BARDA, is to discuss important aspects of Ebola virus and vaccine immunology in order to inform future clinical, scientific and regulation...

videocast.nih.gov/live.asp?live=15350&bhcp=1


acd.od.nih.gov/meetings.htm

[dothedd]

Immunology of Protection from Ebola Virus Infection


The goal of this workshop, which is co-sponsored by FDA, NIAID, DOD, CDC, and BARDA, is to discuss important aspects of Ebola virus and vaccine immunology in order to inform future clinical, scientific and regulatory decision-making related to vaccines against Ebola.

For more information go to ...

respond.niaid.nih.gov/conferences/Ebola/Pages/Immunology%20of%20Protection%20from%20Ebola%20Virus%20Infection.aspx

Friday, December 12, 2014 8:00:00 AM

NIAID/NIH, FDA, BARDA, DoD, CDC

Viewers can submit comments via the Live Event Feedback Form

Runtime: 9 hours, 30 minutes



Completed

Advisory Committee to the Director - December 2014 (Day 2)


ACD full board meeting

For more information go to acd.od.nih.gov

Friday, December 12, 2014 8:00:00 AM

Office of the Director, NIH

Runtime: 5 hours, 45 minutes

[dothedd]

Cash-Rich Novavax Has Upside Potential 

Dec. 22, 2014 1:44 PM ET | About: Novavax, Inc. (NVAX)
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.
Summary

Novavax has received fast-track designation for its RSV candidates.
The company has a massive cash pile, which comes to around 13% of its total market cap.
Despite a flurry of good news, the share prices have remained stagnant.
The current valuations show a significant upside potential based on mean sell-side target price.

Novavax (NASDAQ:NVAX) has been in the news for all the right reasons in the past few months. The company's RSV vaccine candidate has been given the fast-track designation by the US FDA. It has also entered in to more collaboration which means more funds for R& and lesser strain on the cash pile, not that the pile cannot handle any strain. The company has around $178 million in cash which is around 13% of market capitalization. The sell-side target price on Novavax shows an 80% upside.

The Business

Novavax Incorporated is a clinical-stage biopharmaceutical company creating vaccines to address a broad range of infectious diseases. The company produces innovative vaccines to cater to the current and emerging diseases. In order to stay ahead, Novavax is involved in various international collaborations. For example it has collaborated with Cadila Pharmaceuticals of India, LG life sciences of Korea and Isconova AB, a leading company in Sweden. The company has a state of the art manufacturing system and other facilities, which enables it to create vaccinations effectively and efficiently.


CURRENT PRESS RELEASES: 

Novavax to Present at the 26th Annual Piper Jaffray Healthcare Conference
11/26/14
U.S. FDA Grants Fast Track Designation to Novavax’ RSV F-Protein Nanoparticle Vaccine for Protection of Infants via Maternal Immunization
11/20/14
Novavax Initiates Phase 2 Clinical Trial of Quadrivalent Seasonal Influenza VLP
11/17/14
Novavax to Present at the Jefferies Global Healthcare Conference
11/13/14
Novavax Initiates Phase 1 Clinical Trial of RSV F Vaccine in Pediatric Subjects
11/10/14
Novavax and Collaborators Make Multiple Presentations at the 9th International Respiratory Syncytial Virus Symposium in South Africa, November 9-13, 2014
11/06/14

[dothedd]

2 Small Vaccine Makers With Lots Of Upside
By Bret Jensen of Investors Alley
Friday, January 2, 2015 7:13 PM EST


One of the major themes to the markets and global economy over the past few decades has been the consistently increasing “globalization” of the world. This has had substantial impacts to trade, economic growth, geopolitics, labor dislocation and, of course, travel.

If one wanted to visit Europe from the United States one hundred years ago it would involve making one’s way to a major port, shelling out a huge amount of cash for passage on an ocean liner and many, many days of voyage across the pond. Now a person can fly directly to many capitals of Europe from multiple destination points in the States in 8-12 hours.

The faster and cheaper means of travel has opened up the world to more people than ever before. On the whole, this development is very positive on a variety of fronts. However, the increase mingling of people from around the globe does have its downside. One of the major risks that have increased because of this trend is the increased risk of a major pandemic.

Over the past decade the world has seen the outbreak of SARS and bird flu in Asia and MERS in the Middle East. Recently markets were rattled by the first cases of Ebola in the United States. It is important to remember how deadly a global contagion can become. The Spanish Flu outbreak of 1918-1919 killed more people worldwide than World War I.

This makes the vaccine space very interesting at the present moment and luckily some major progress is being made to develop vaccines for known scourges of humanity as well as some of the new ones that will surface due to the greater global interactivity brought about by an immense increase in travel. Here are a couple of attractive but speculative small cap concerns that play in this space.

NVAX (NOVAVAX)

Long time readers of mine from SeekingAlpha and Real Money Pro will not be surprised that Novavax (NASDAQ: NVAX) is on my short list of attractive vaccine makers. I first highlighted this promising small cap concern in March of 2012 when its stock traded at just $1.30 a share. The company has started to deliver against its promise and the equity is closing in on $6.00 a share. I have taken some profits on this better than four bagger but still own a stake in this biotech firm. With its recent rally, the market capitalization of Novavax has shot up to some $1.4 billion.

Despite the huge rise in the stock over the past almost three years, there are still plenty of reasons to like the long-term prospects of Novavax. The company received FDA fast track approval in late November for its RSV F-Protein nanoparticle vaccine candidate for protection of infants via maternal immunization. This disease causes approximately 150,000 infants to be hospitalized annually in the United States.

In addition, the Department of Health & Human Services exercised their option with Novavax in September to have the company continue its work on advanced development of its recombinant seasonal and pandemic influenza vaccines and manufacturing capabilities for pandemic preparedness. This provided Novavax with continued access to the remainder of the $97M base period funding, which has just over $30 million remaining on the agreement plus an additional $70 million to support development activities leading to a planned Phase III clinical trial in 2016. Obviously this is a huge vote of confidence and could lead to major positive catalysts in the years ahead. The company has a deep pipeline of early stage vaccines in development which provides the multiple “shots on goal” I like to see before I make an investment in this inherently volatile space.

Chart I

Novavax is currently posting small losses. If vaccines in development successfully move through the development process, I expect the company to be profitable by 2017. The company has over $170 million in net cash on the balance sheet and analysts are still positive on the equity with a median price target of $10.00 a share by the seven analysts that cover the company.

CONTINUED: www.talkmarkets.com/content/us-markets/2-small-vaccine-makers-with-lots-of-upside?post=55818

[dothedd]

France and Italy ban products from Indian companies


January 6, 2015 


While FDA regulatory action against Indian companies has drawn the media spotlight the last couple of years, European regulators also have been finding problems with some Indian plants. Both France and Italy took action against Indian drug manufacturers last month, finding them out of compliance and limiting product sales as a result.

France issued a statement of noncompliance and banned products from a Medreich plant in Andhra Pradesh following a May inspection, which was a follow-up to one the year before. According to the report, inspectors found 58 deficiencies, including one concerning data being faked that was classified as critical. Another 29 were classified as major and included a variety of problems related to cross-contamination, inadequate visual inspections, inadequate equipment maintenance, a "poor level of quality management," as well as with microbial testing. According to the report, the problems affected both sterile and nonsterile drugs.

The Italian Medicines Agency recommended products be banned from a Sri Krishna Pharmaceuticals facility in Hyderabad, also in Andhra Pradesh, after finding 10 issues that inspectors considered major. They discovered that employees were backdating testing equipment and writing over failed test results repeatedly until they got an acceptable result. "Notably, after subsequent investigation it was found that the Master Batch Record (version 0) had been back-dated by the most responsible persons within your firm's Quality and Manufacturing departments, which was confirmed by these persons during our inspection," the agency wrote to Sri Krishna.

[dothedd]

NOVAVAX PPS 1 9 15 Friday

5.95 Jan 8, 4:00PM EST
Pre-Market : 6.09 0.15 (2.53%) 9:28AM EST
Pre-Market : 6.03 0.09 (1.52%) 9:29AM EST
6.010 0.1465(2.46%) 9:34AM EST
6.0965 0.1465(2.46%) 9:34AM EST
6.08 0.13(2.18%) 9:34AM EST
Day's Range: 6.0499 - 6.13
52wk Range: 3.34 - 6.95


6.0599 0.1099(1.85%)
6.05 0.10(1.68%) 9:36AM EST
6.04 0.09(1.51%) 9:36AM EST
6.05 0.10(1.68%) 9:36AM EST

Day's Range: 6.03 - 6.13
52wk Range: 3.34 - 6.95

Volume: 337,564

Avg Vol (3m): 3,828,620
6.0570 0.1070(1.80%) 9:37AM EST
6.08 0.13(2.18%) 9:37AM EST
6.09 0.14(2.35%) 9:38AM EST
6.12 0.17(2.86%) 9:38AM EST
6.08 0.13(2.18%) 9:38AM EST
6.0899 0.1399(2.35%) 9:38AM EST
6.10 0.15(2.52%) 9:39AM EST
6.12 0.17(2.86%) 9:39AM EST
6.13 0.18(3.03%) 9:39AM EST
6.12 0.17(2.86%) 9:40AM EST
6.1360 0.1860(3.13%) 9:40AM EST
6.15 0.20(3.36%) 9:40AM EST
6.16 0.21(3.53%) 9:40AM EST
6.1799 0.2299(3.86%) 9:41AM EST
6.1755 0.2255(3.79%) 9:41AM EST
Day's Range: 6.03 - 6.18
52wk Range: 3.34 - 6.95

Volume: 661,878

6.1760 0.2260(3.80%) 9:41AM EST
6.18 0.23(3.87%) 9:41AM EST
6.1855 0.2355(3.96%) 9:42AM EST –
6.17 0.22(3.70%) 9:42AM EST –
6.1772 0.2272(3.82%) 9:42AM EST –
6.1772 0.2272(3.82%) 9:42AM EST –
6.17 0.22(3.70%) 9:47AM EST
6.18 0.23(3.86%) 9:48AM EST
6.17 0.22(3.70%) 9:48AM EST
6.16 0.22(3.70%) 9:48AM EST
6.17 0.22(3.70%) 9:48AM EST
6.16 0.21(3.53%) 9:49AM EST
6.18 0.23(3.78%) 9:49AM EST
6.18 0.23(3.80%) 9:49AM EST
6.20 0.26(4.37%) 9:50AM EST
6.21 0.26(4.37%) 9:50AM EST
6.22 0.27(4.54%) 9:51AM EST

Volume: 1,108,220
Volume: 1,114,080

6.23 0.21(3.53%) 9:52AM EST
6.16 0.21(3.53%) 9:52AM EST
6.24 0.29(4.87%) 9:52AM EST
6.20 0.25(4.20%) 9:53AM EST
6.21 0.26(4.29%) 9:53AM EST
6.20 0.25(4.20%) 9:54AM EST
6.17 0.22(3.70%) 9:54AM EST
6.22 0.27(4.53%) 9:54AM EST
6.17 0.22(3.70%)
6.22 0.27(4.54%) 9:55AM EST
6.20 0.25(4.20%) 9:55AM EST
6.22 0.27(4.54%) 9:56AM EST
6.17 0.22(3.70%) 9:56AM EST

Volume: 1,226,612

6.23 0.27(4.54%)
6.22 0.27(4.54%)
6.24 0.30(4.96%) 9:57AM EST
6.26 0.31(5.17%) 9:57AM EST
6.25 0.30(5.01%) 9:57AM EST
6.24 0.30(5.04%) 9:57AM EST
6.25 0.30(5.04%) 9:57AM EST
6.25 0.30(5.04%) 9:58AM EST
6.26 0.31(5.13%) 9:58AM EST
6.24 0.27(4.56%) 9:59AM EST
6.22 0.27(4.56%) 9:59AM EST
6.25 0.28(4.70%) 9:59AM EST
6.23 0.28(4.70%) 9:59AM EST
6.22 0.27(4.54%) 9:59AM EST
6.21 0.26(4.37%) 10:05AM EST
6.2050 0.2550(4.29%) 10:05AM EST
6.23 0.28(4.71%) 10:07AM EST

Volume: 1,680,990

6.21 0.26(4.39%) 10:08AM EST
6.22 0.27(4.54%) 10:08AM EST
6.26 0.31(5.21%) 10:10AM EST
6.28 0.33(5.55%) 10:11AM EST
6.29 0.33(5.55%) 10:11AM EST
6.28 0.33(5.55%) 10:11AM EST 1,952,251
6.27 0.33(5.55%) 10:12AM EST
6.28 0.33(5.55%) 10:12AM EST
6.29 0.34(5.71%) 10:13AM EST
6.23 0.28(4.71%) 10:13AM EST
6.29 0.34(5.71%) 10:13AM EST
6.3790 0.4290(7.21%) 10:40AM EST
6.38 0.43(7.23%) 10:41AM EST
6.30 0.35(5.88%) 4:00PM EST

After Hours : 6.33 0.03 (0.48%) 4:05PM EST 
6.30 0.35(5.88%) 4:00PM EST
After Hours : 6.31 0.00 (0.00%) 4:26PM EST

Day's Range: 6.03 - 6.48
52wk Range: 3.34 - 6.95

Volume: 7,322,283 

Avg Vol (3m): 3,828,620

[dothedd]

NOVAVAX EBOLA PROGRAM


  VIDEO:  www.novavax.com/go.cfm?do=Page.View&pid=177